Clal Biotechnology Industries - Gamida Cell lists on NASDAQ
Q318 was an active period for Clal Biotechnology Industries’ (CBI’s) portfolio of investments on multiple fronts. First and most notably, Gamida Cell completed a ~$53m IPO on the NASDAQ under the symbol GMDA and plans to present NiCord immune reconstruction (IR) data at the American society of Haematology (ASH) meeting on 1 December. We expect Anchiano to list in the US in the coming months pending market conditions. MediWound slightly delayed its NexoBrid Phase III data readout by one quarter.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.